STOK Stock Risk & Deep Value Analysis
Stoke Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About STOK Stock
We analyzed Stoke Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran STOK through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is STOK Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for STOK?
- ⚠
Negative or inconclusive data from Phase 3 MONARCH study
- ⚠
Significant delays in clinical trial enrollment or timelines
- ⚠
Increased competition in Dravet Syndrome with superior therapies
- ⚠
Unexpected safety signals emerging from clinical trials
Unlock STOK Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Stoke Therapeutics Inc (STOK) Do?
Market Cap
$1.40B
Sector
Healthcare
Industry
Biotechnology
Employees
128
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Visit Stoke Therapeutics Inc WebsiteIs STOK Stock Undervalued?
Unlock the full AI analysis for STOK
Get the complete DVR score, risk analysis, and more
Is STOK Financially Healthy?
P/E Ratio
29.38
Does STOK Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The TANGO platform's ability to selectively upregulate protein expression via antisense oligonucleotides creates a unique, patent-protected approach that is difficult to replicate. Successful clinical validation of STK-001 will further entrench this advantage and validate the platform for future indications.
Moat Erosion Risks
- •Patent challenges or expiry on ASO technology
- •Development of alternative therapies for Dravet Syndrome with superior efficacy or safety profiles
- •Inability to translate TANGO platform success to subsequent pipeline assets
STOK Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive STOK Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (expected early March 2026)
- •Updates on Phase 3 MONARCH study enrollment and progress (Q2/Q3 2026)
- •Presentation of additional STK-001 data from ongoing cohorts at scientific conferences (H1 2026)
Medium-Term (6-18 months)
- •Announcement of a new preclinical candidate advancing towards IND-enabling studies (H2 2026)
- •Potential for interim data readouts or adaptive trial design updates from Phase 3 MONARCH (H1 2027)
- •Strategic partnership opportunities for pipeline assets leveraging TANGO platform (H2 2026 - H1 2027)
Long-Term (18+ months)
- •Top-line data from pivotal Phase 3 MONARCH study for STK-001 (late 2027 - early 2028)
- •Regulatory filings (NDA/MAA) for STK-001 (2028)
- •Commercial launch of STK-001 and pipeline expansion into other rare genetic diseases (2029+)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for STOK?
- ✓
Positive enrollment and interim safety/efficacy updates from Phase 3 MONARCH study
- ✓
Achievement of further pipeline milestones (e.g., new INDs)
- ✓
Cash burn rate relative to cash on hand and future financing needs
Bull Case Analysis
See what could go right with Premium
Compare STOK to Similar Stocks
See how Stoke Therapeutics Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for STOK (Stoke Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
